絞り込み

16506

広告

Tailored first-line and second-line CDK4-targeting treatment combinations in mouse models of pancreatic cancer.

著者 Chou A , Froio D , Nagrial AM , Parkin A , Murphy KJ , Chin VT , Wohl D , Steinmann A , Stark R , Drury A , Walters SN , Vennin C , Burgess A , Pinese M , Chantrill LA , Cowley MJ , Molloy TJ , , Waddell N , Johns A , Grimmond SM , Chang DK , Biankin AV
Gut.2017 Oct 28 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (25view , 0users)

Full Text Sources

Miscellaneous

Extensive molecular heterogeneity of pancreatic ductal adenocarcinoma (PDA), few effective therapies and high mortality make this disease a prime model for advancing development of tailored therapies. The p16-cyclin D-cyclin-dependent kinase 4/6-retinoblastoma (RB) protein (CDK4) pathway, regulator of cell proliferation, is deregulated in PDA. Our aim was to develop a novel personalised treatment strategy for PDA based on targeting CDK4.
PMID: 29080858 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード